ZAI LAB LIMITED |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.36 USD | +2.43% |
|
+6.73% | -43.69% |
Financials (USD)
| Sales 2024 * | 379M | Sales 2025 * | 635M | Capitalization | 1.48B |
|---|---|---|---|---|---|
| Net income 2024 * | -317M | Net income 2025 * | -126M | EV / Sales 2024 * | 2.61 x |
| Net cash position 2024 * | 491M | Net cash position 2025 * | 275M | EV / Sales 2025 * | 1.9 x |
| P/E ratio 2024 * |
-4.58
x | P/E ratio 2025 * |
-20
x | Employees | 2,175 |
| Yield 2024 * |
-
| Yield 2025 * |
1.33% | Free-Float | 89.99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zai Lab Limited
More recommendations
More press releases
More news
| 1 day | +6.54% | ||
| 1 week | +5.56% | ||
| Current month | -6.43% | ||
| 1 month | -7.35% | ||
| 3 months | -33.08% | ||
| 6 months | -37.31% | ||
| Current year | -45.15% |
1 week
13.48
15.27
1 month
13.4816.73
Current year
13.4827.87
1 year
13.4839.50
3 years
13.48181.92
5 years
13.48193.54
10 years
13.48193.54
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Du
CEO | Chief Executive Officer | 59 | 14-03-31 |
Ya jing Chen
DFI | Director of Finance/CFO | 56 | 21-08-31 |
Joshua Smiley
PSD | President | 54 | 22-07-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John D. Diekman
BRD | Director/Board Member | 81 | 16-12-31 |
Peter Wirth
BRD | Director/Board Member | 73 | 16-12-31 |
Lonnie Moulder
BRD | Director/Board Member | 66 | 18-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.29% | 4 M€ | -27.92% | ||
| 1.04% | 2 M€ | -20.02% | - | |
| 0.75% | 96 M€ | -.--% | - | |
| 0.27% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 15.38 | +2.57% | 270 351 |
| 24-04-22 | 14.99 | +6.54% | 455,452 |
| 24-04-19 | 14.07 | -1.05% | 465,965 |
| 24-04-18 | 14.22 | +3.64% | 694,734 |
| 24-04-17 | 13.72 | -4.85% | 397,850 |
Delayed Quote Nasdaq, April 22, 2024 at 04:00 pm EDT
More quotes
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Sector
Pharmaceuticals
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
14.99
USD
Average target price
52.5
USD
Spread / Average Target
+250.27%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -45.15% | 1.48B | |
| -2.68% | 85.68B | |
| +5.53% | 41.4B | |
| -24.99% | 28.22B | |
| +55.96% | 24.64B | |
| -7.19% | 16.98B | |
| -34.20% | 13.29B | |
| -17.31% | 11.66B | |
| -11.43% | 11.65B | |
| -0.82% | 8.18B |
- Stock Market
- Equities
- ZLAB Stock
